Quantifies renal impact in mCRPC, indicating the need for monitoring due to dose effects.
Lu]Lu-PSMA-617 is associated with a slight long-term average decline in eGFR. Although this is unlikely to be clinically relevant for late-stage mCRPC, the cumulative dose effect warrants careful monitoring in earlier disease stages.
No takes yet. Share an insight, caveat, or question.
Büttner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: